Revance Therapeutics (RVNC) Tops Q1 EPS by 12c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.71), $0.12 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• Coty (COTY) Misses Q4 EPS by 1c, offers outlook